Risk factors for relapse of visceral leishmaniasis in Georgia

Trop Med Int Health. 2011 Feb;16(2):186-92. doi: 10.1111/j.1365-3156.2010.02694.x. Epub 2010 Dec 8.

Abstract

The number of relapses in patients treated for visceral leishmaniasis (VL) has increased, thus identifying prognostic factors may aid decisions on treatment. Demographic and clinical information was abstracted from medical records of patients diagnosed and treated in Georgia from 2002 to 2004. The 300 persons with VL were primarily children <5 years (73.3%), and ∼44% had delays in diagnosis of more than 30 days from symptom onset. All patients received standard therapy with pentavalent antimony (20 mg/kg/day), most for 20-25 days. Factors significantly associated with VL relapse were delay in diagnosis for >90 days (RR = 4.21, 95% CI: 1.58, 11.16), haemoglobin level <60 g/l (RR = 11.96, 95% CI: 4.12, 34.76) and age <1 year (RR = 2.36, 95% CI: 0.96, 5.80). Physician and public education is needed to reduce delays in diagnosis. Prolonging treatment for 30 days (e.g. WHO recommendation) or implementing new regimens may reduce the number of relapses.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Age Factors
  • Antiprotozoal Agents / therapeutic use
  • Child
  • Child, Preschool
  • Delayed Diagnosis
  • Female
  • Georgia (Republic) / epidemiology
  • Hemoglobins / analysis
  • Humans
  • Infant
  • Leishmaniasis, Visceral / diagnosis
  • Leishmaniasis, Visceral / drug therapy
  • Leishmaniasis, Visceral / epidemiology
  • Leishmaniasis, Visceral / etiology*
  • Male
  • Meglumine / therapeutic use
  • Meglumine Antimoniate
  • Organometallic Compounds / therapeutic use
  • Prognosis
  • Recurrence
  • Risk Factors

Substances

  • Antiprotozoal Agents
  • Hemoglobins
  • Organometallic Compounds
  • Meglumine
  • Meglumine Antimoniate